about
Tackling ALK in non-small cell lung cancer: the role of novel inhibitorsCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerTrastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplificationEffect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell LinesThe Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Maintenance therapy in NSCLC: why? To whom? Which agent?Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practiceEpidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.CT-guided biopsy of pulmonary nodules: is pulmonary hemorrhage a complication or an advantage?Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method.Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe.Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice?Multi-target inhibitors in non-small cell lung cancer (NSCLC)."Pseudocavitation" in thymic carcinoma during treatment with sunitinib.Combination of target agents: challenges and opportunities.ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatinCurrent status of second-line treatment and novel therapies for small cell lung cancer.Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma.Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.Is immunohistochemistry always required to diagnose lung cancer?MET and ALK as targets for the treatment of NSCLC.Targeting the MET gene for the treatment of non-small-cell lung cancer.MET and Small-Cell Lung Cancer.Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?Curved Needles in CT-Guided Fine Needle Biopsies of Abdominal and Retroperitoneal Small Lesions.FGFR as potential target in the treatment of squamous non small cell lung cancer.Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel.Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors.Classification of different patterns of pulmonary adenocarcinomas.
P50
Q26740329-BD29DB80-FE18-44BA-83B5-631C21094269Q26775376-6E8D1AA7-3F1F-4C2F-ADE6-66E18006C8B8Q27853015-DCF1E649-88AC-461A-BD41-7D13A8538A69Q28534577-C5311E59-BC50-4DB4-BE26-23ABA50DD3D2Q28550693-B2F2E560-151B-4933-96D3-ACE21C37C29EQ30249696-9E91748B-81B3-4FD9-9DC1-27256815A33CQ33286793-FD3AD664-04A6-4D82-A998-0F0A72C83D93Q33379422-E9836183-0F85-4F09-98D7-43DC6D4F8EE2Q33409103-145BD02E-E102-4144-9CE9-CF8414862F9DQ33892582-B72ABB2F-DBCF-46B7-94BA-6301FA211533Q34550460-F3A6AB6E-9072-471D-BF5E-C971144630FAQ35041521-B8C4EBC5-B82C-48AB-AAB2-839C14CBA8D8Q35200569-BCCC9393-38B8-464B-99C1-0BA90E1DE97BQ35699574-5CA3584C-72CE-4D81-BDDB-D06B88603BFDQ35721004-636C1C9E-40FA-47DB-A958-67156A91CCD4Q35842078-E3EF8525-4F43-46BA-8F05-4372CFB121E4Q35879879-68477E85-D997-40BE-BC63-0DFC87972E8DQ36028725-A4A294D3-3743-4155-AEAF-91F799CE0B66Q36103157-30C6B500-520C-4138-B3CF-4E4B5EC88185Q36248579-28743F57-8032-40E7-A343-82AA5D378A66Q36315282-0E60F527-99B5-456D-8B77-E1FCF505E538Q36445843-E9E53165-F267-4F5A-B5F4-33C5F0A1429CQ36700592-B9F70EB3-4568-46CF-BF62-769DEA6A9F79Q36800929-FB49DEE4-C1BB-48BB-B49A-7C3EEBA5FC64Q36893674-704F13C3-7756-4B4B-AE2D-13144609CD9AQ36924993-33C15678-A84F-4FFB-BA2A-52CF292B6026Q37706672-32AE0547-9FFE-4F58-8E58-351C7071D97AQ37736223-81854693-0CAE-4AB2-B303-937B2ED11B1AQ37952236-530AE72C-5EF7-4EF6-AD7B-D09FC7C08E8CQ38128487-4DE5F3DE-2DEB-41C7-8EE0-78C7EDDD7980Q38153827-97FD73A5-7367-4D50-8DD0-532F01789F12Q38172700-85AE6525-D4A2-4210-9B10-1047E8AC3690Q38260120-97C31935-E7AA-43DE-91F5-68586200DA05Q38429429-DE070C06-A219-435B-A120-378FD41D4DCEQ38435145-81680B75-4D99-4E14-93E9-B2C2357DC2EFQ38441169-DC578A68-4CC0-4ABC-B580-D0E3D7C5E506Q38470406-A0356AB9-F8AB-441E-8065-0D4F7CC2EDEEQ38491810-25BAA1A3-3A85-44C7-A36B-51C5946A1558Q38564088-35B3F147-4E18-4B7D-80B4-642380309739Q38574971-C6F5D59D-F24A-4AAE-A1E3-DD15BDF1AFF1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marcello Tiseo
@ast
Marcello Tiseo
@en
Marcello Tiseo
@es
Marcello Tiseo
@nl
Marcello Tiseo
@sl
type
label
Marcello Tiseo
@ast
Marcello Tiseo
@en
Marcello Tiseo
@es
Marcello Tiseo
@nl
Marcello Tiseo
@sl
prefLabel
Marcello Tiseo
@ast
Marcello Tiseo
@en
Marcello Tiseo
@es
Marcello Tiseo
@nl
Marcello Tiseo
@sl
P106
P31
P496
0000-0002-9553-8465